Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
TSHA

TSHA - Taysha Gene Therapies Inc Stock Price, Fair Value and News

$4.48-0.28 (-5.88%)
Market Closed

10/100

TSHA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

10/100

TSHA

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.73

Target 3M

$4.19

Target 6M

$3.96

TSHA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TSHA Price Action

Last 7 days

-6.3%

Last 30 days

-20.7%

Last 90 days

-8.8%

Trailing 12 Months

198.7%

TSHA RSI Chart

TSHA Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

TSHA Valuation

Market Cap

1.2B

Price/Earnings (Trailing)

-12.28

Price/Sales (Trailing)

194.48

Price/Free Cashflow

-13.72

TSHA Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.73

Target 3M

$4.19

Target 6M

$3.96

TSHA Fundamentals

TSHA Revenue

Revenue (TTM)

6.3M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

TSHA Earnings

Earnings (TTM)

-99.9M

Earnings Growth (Yr)

-28.24%

Earnings Growth (Qtr)

-21.77%

TSHA Profitability

Return on Equity

-45.63%

Return on Assets

-31.57%

Free Cashflow Yield

-7.29%

TSHA Investor Care

Shares Dilution (1Y)

33.66%

Diluted EPS (TTM)

-0.33

TSHA Alerts

  • 3 major insider sales recently.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20257.2M8.1M6.3M0
202414.2M12.9M9.9M8.3M
20235.7M9.0M12.2M15.5M
20220002.5M
Get all data in R, Python etc through our Historical Stock Data APIs

About Taysha Gene Therapies Inc

TSHA
Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 Deficiency; and TSHA-101 for the treatment of GM2 gangliosidosis. Taysha Gene Therapies, Inc. has a strategic partnership with The University of Texas Southwestern Medical Center to develop and commercialize transformative gene therapy treatments. The company was incorporated in 2019 and is based in Dallas, Texas.
 CEO
 WEBSITEtayshagtx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES65

Taysha Gene Therapies Inc Frequently Asked Questions

TSHA is the stock ticker symbol of Taysha Gene Therapies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Taysha Gene Therapies Inc is 1.23 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check TSHA's fair value in chart for subscribers.

The fair value guage provides a quick view whether TSHA is over valued or under valued. Whether Taysha Gene Therapies Inc is cheap or expensive depends on the assumptions which impact Taysha Gene Therapies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TSHA.

As of Wed Jan 28 2026, TSHA's PE ratio (Price to Earnings) is -12.28 and Price to Sales (PS) ratio is 194.48. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TSHA PE ratio will change depending on the future growth rate expectations of investors.